Pure Global
NCT06356259

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
ImmunoRx Pharma Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Participants
Drug/Device/Intervention
IRX-010
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
ImmunoRx Pharma Inc.
Location
Groningen, Netherlands
Timeline & enrollment
Phase
Phase 1
Start date
Jun 07, 2023
End date
Jan 22, 2025
Enrollment
81 participants
Primary outcome

Number of participants with Serious Adverse Events,Number of participants with Treatment-Emergent Adverse Events

Summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with
 intravenous(IV) administration of IRX-010 in Healthy Participants.

ICD-10 classifications
Seeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personRoutine general health check-up of sports teamsObesityPersons with potential health hazards related to communicable diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06356259
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06356259 through Pure Global AI's free database. This Phase 1 trial is sponsored by ImmunoRx Pharma Inc. and is currently Recruiting. The study focuses on Healthy Participants. Target enrollment is 81 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.